12,600 Shares in ICU Medical, Inc. (NASDAQ:ICUI) Acquired by Hussman Strategic Advisors Inc.

Hussman Strategic Advisors Inc. acquired a new position in shares of ICU Medical, Inc. (NASDAQ:ICUI) during the 4th quarter, HoldingsChannel.com reports. The firm acquired 12,600 shares of the medical instruments supplier’s stock, valued at approximately $1,955,000.

A number of other large investors also recently made changes to their positions in the stock. Venturi Wealth Management LLC lifted its stake in shares of ICU Medical by 64.0% in the 4th quarter. Venturi Wealth Management LLC now owns 528 shares of the medical instruments supplier’s stock valued at $82,000 after purchasing an additional 206 shares during the period. Principal Financial Group Inc. raised its stake in ICU Medical by 4.1% during the 4th quarter. Principal Financial Group Inc. now owns 132,099 shares of the medical instruments supplier’s stock worth $20,498,000 after buying an additional 5,162 shares during the period. State of New Jersey Common Pension Fund D raised its stake in ICU Medical by 1.6% during the 4th quarter. State of New Jersey Common Pension Fund D now owns 12,370 shares of the medical instruments supplier’s stock worth $1,919,000 after buying an additional 191 shares during the period. New York State Teachers Retirement System raised its stake in ICU Medical by 6.7% during the 4th quarter. New York State Teachers Retirement System now owns 28,343 shares of the medical instruments supplier’s stock worth $4,398,000 after buying an additional 1,777 shares during the period. Finally, Equitable Trust Co. raised its stake in ICU Medical by 1.6% during the 4th quarter. Equitable Trust Co. now owns 5,297 shares of the medical instruments supplier’s stock worth $822,000 after buying an additional 84 shares during the period. Institutional investors and hedge funds own 96.10% of the company’s stock.

Insider Activity

In related news, Director David C. Greenberg sold 972 shares of ICU Medical stock in a transaction dated Wednesday, November 27th. The stock was sold at an average price of $158.11, for a total transaction of $153,682.92. Following the completion of the transaction, the director now owns 5,037 shares in the company, valued at approximately $796,400.07. This trade represents a 16.18 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Vivek Jain sold 12,000 shares of ICU Medical stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $162.91, for a total value of $1,954,920.00. Following the transaction, the chief executive officer now owns 104,593 shares of the company’s stock, valued at $17,039,245.63. The trade was a 10.29 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 17,737 shares of company stock worth $2,879,752 in the last quarter. Corporate insiders own 6.70% of the company’s stock.

ICU Medical Price Performance

Shares of NASDAQ ICUI opened at $164.13 on Thursday. The stock has a market capitalization of $4.02 billion, a price-to-earnings ratio of -35.91 and a beta of 0.63. The business has a 50-day moving average of $160.87 and a 200-day moving average of $165.37. The company has a debt-to-equity ratio of 0.75, a current ratio of 2.29 and a quick ratio of 1.03. ICU Medical, Inc. has a fifty-two week low of $93.36 and a fifty-two week high of $196.26.

Analysts Set New Price Targets

Several analysts recently commented on ICUI shares. KeyCorp raised their price objective on ICU Medical from $198.00 to $209.00 and gave the stock an “overweight” rating in a research note on Wednesday, November 13th. Jefferies Financial Group upgraded ICU Medical from a “hold” rating to a “buy” rating and set a $200.00 target price for the company in a report on Wednesday, December 11th. Needham & Company LLC reiterated a “hold” rating on shares of ICU Medical in a report on Wednesday, November 13th. Finally, StockNews.com upgraded ICU Medical from a “hold” rating to a “buy” rating in a report on Wednesday, November 20th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $199.67.

ICU Medical Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.